Genmab A/S (OTCMKTS:GNMSF) Sees Large Drop in Short Interest

Key Points

• Short interest in Genmab A/S dropped by 56.4% in July, with total shares short decreasing from 69,900 to 30,500.
• The company's stock price rose by 7.4%, reaching $232.30, and the stock has a market capitalization of $15.35 billion.
• Genmab's latest quarterly earnings report showed earnings per share of $5.42, exceeding analysts' expectations, despite revenue falling short of estimates at $925 million.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 30,500 shares, adropof56.4% from the July 15th total of 69,900 shares. Approximately0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 305.0 days. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 305.0 days. Approximately0.0% of the shares of the company are sold short.

Genmab A/S Stock Up 7.4%

Shares of OTCMKTS GNMSF traded up $15.99 during mid-day trading on Friday, reaching $232.30. 25 shares of the company were exchanged, compared to its average volume of 519. Genmab A/S has a twelve month low of $170.00 and a twelve month high of $282.06. The stock has a market capitalization of $15.35 billion, a P/E ratio of 11.66 and a beta of 0.93. The company's 50-day simple moving average is $215.84 and its 200-day simple moving average is $207.31.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $5.42 earnings per share for the quarter, topping the consensus estimate of $3.99 by $1.43. The firm had revenue of $925.00 million for the quarter, compared to the consensus estimate of $949.06 million. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.